PATENT

1949 WHAT IS CLAIMED IS:

5

5

- 1. A method of treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to reduce the secretion.
- 2. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's nerve plexus in an amount of between about 0.01 and about 50 units.
- 3. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's ganglion in an amount of between about 0.01 and about 50 units.
- 4. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's spinal cord in an amount of between about 0.01 and about 50 units.
- 5. The method according to claim 1 wherein the Botulinum toxin type A is administered to the patient's central nervous system in an amount of between about 0.01 and about 50 units.
- 6. A method for relieving pain associated with smooth muscle disorders, including spasms in the sphincters of the cardiovascular arteriol, gastrointestinal system, urinary, gall bladder and rectum, said method comprising administering to the patient a

-22- PATENT

therapeutically effective amount of Botulinum toxin type A in order to relieve pain.

- 7. The method according to claim 6 wherein the Botulinum toxin type A is administered to the patient's pyloric valve in an amount between about 1 and about 50 units.
- 8. method for treating smooth muscle disorders, including spasms in the sphincters of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, said comprising administering to the patient therapeutically effective amount of Botulinum toxin type A in order to lessen the spasms.

5

5

- 9. The method according to claim 8 wherein the Botulinum toxin type A is administered to the patient's pyloric valve in an amount between about 1 and about 50 units.
- 10. A method for relieving pain associated with smooth muscle disorders, including spasms in the lower gastrointestinal muscles and rectum, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to relieve pain.
- 11. The method according to claim 10 wherein the Botulinum toxin type A is administered to the patient's lower colon in an amount between about 0.01 and about 50 units.
- 12. A method for relieving pain associated with smooth muscle disorders, including spasms in the

PATENT

sphincters lower gastrointestinal muscles and rectum, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A in order to lessen the spasms.

- 13. The method according to claim 12 wherein the Botulinum toxin type A is administered to the patient's lower colon in an amount between about 0.01 and about 50 units.
- 14. A method for relieving pain associated with muscle spasms in conditions secondary to sports injuries, said method comprising administering to a patient a therapeutically effective amount of a Botulinum toxin of a type having short duration activity in order to relieve pain.
- 15. The method according to claim 14 wherein the Botulinum toxin comprises Botulinum toxin type F.
- 16. The method according to claim 15 wherein the therapeutic amount comprises a dose of between about 1 and about 10 units.
- 17. The method according to claim 16 wherein the muscle spasms occur in a patient's thigh and the Botulinum toxin is administered into the thigh
- 18. A method for relieving pain associated with contractions in arthritis, said method comprising administering to a patient a therapeutically effective amount of a Botulinum toxin in order to relieve pain.
- 19. A method for treating swallowing disorders, including spasms, said method comprising administering

5

5

5

to the patient a therapeutically effective amount of Botulinum toxin type A.

10

20. A method for treating tension headache comprising administering to the patient a therapeutically effective amount of Botulinum toxin type A.